Clinical trials in Swidnica – page 19

985 clinical trials in Swidnica, Poland across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in PolandBadaniaKliniczne.pl

Swidnica at a glance

985

clinical trials

Research sites1

Quick filters

985 trials in Swidnica

Open in trial search

Coronary artery disease+1

Recruiting

Study comparing high-dose and low-dose aspirin with prasugrel and aspirin combination in patients after coronary artery bypass grafting surgery

Registered drugNo placebo

Study comparing high-dose and low-dose aspirin with prasugrel and aspirin combination in patients after coronary artery bypass grafting surgery

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Acetylsalicylic Acid
Sponsor:Agencja Badań Medycznych

Contact Research Centre

Alopecia areata

Recruiting

Long-term safety and effectiveness study of ritlecitinib in children with severe alopecia areata who completed previous trials B7981027 or B7981031

Investigational

Long-term safety and effectiveness study of ritlecitinib in children with severe alopecia areata who completed previous trials B7981027 or B7981031

Investigational

Poland

Participants:0–17 years
Sponsor:Pfizer Inc.

Contact Research Centre

Acute myeloid leukaemia+3

Recruiting

Study comparing standard and reduced intensity treatment in patients with acute myeloid leukemia or chronic lymphocytic leukemia who have no detectable disease after initial therapy

Registered drugNo placebo

Study comparing standard and reduced intensity treatment in patients with acute myeloid leukemia or chronic lymphocytic leukemia who have no detectable disease after initial therapy

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Busulfan
Sponsor:Medizinische Hochschule Hannover

Contact Research Centre

Triple negative breast cancer

Recruiting

Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

Registered drugNo placebo

Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Non-small cell lung cancer+2

Recruiting

Study of THIO and cemiplimab compared to chemotherapy in patients with advanced non-small cell lung cancer who have received two previous treatments

Registered drugNo placebo

Study of THIO and cemiplimab compared to chemotherapy in patients with advanced non-small cell lung cancer who have received two previous treatments

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Cemiplimab
Sponsor:Maia Biotechnology Inc.

Contact Research Centre

Transitional cell cancer of the renal pelvis and ureter

Recruiting

Study of UGN-104 (mitomycin) treatment for patients with low-grade upper tract urothelial cancer

InvestigationalNo placebo

Study of UGN-104 (mitomycin) treatment for patients with low-grade upper tract urothelial cancer

InvestigationalNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Mitomycin
Sponsor:Urogen Pharma Ltd.

Contact Research Centre

Atrial fibrillation

Recruiting

Study of AP31969 compared to placebo to control heart rhythm in patients with atrial fibrillation

Investigational

Study of AP31969 compared to placebo to control heart rhythm in patients with atrial fibrillation

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:AP31969 sulfate
Sponsor:Acesion Pharma ApS

Contact Research Centre

IgA nephropathy

Recruiting

Study of Mezagitamab in Adults with Primary IgA Nephropathy (Berger's Disease) to Reduce Protein in Urine

Investigational

Study of Mezagitamab in Adults with Primary IgA Nephropathy (Berger's Disease) to Reduce Protein in Urine

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:Mezagitamab
Sponsor:Takeda Development Center Americas Inc.

Contact Research Centre

Colitis ulcerative

Recruiting

Study of RO7837195 injection compared to placebo to treat moderate to severe ulcerative colitis

Investigational

Study of RO7837195 injection compared to placebo to treat moderate to severe ulcerative colitis

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:RO7837195
Sponsor:Genentech Inc.

Contact Research Centre

Asthma

Recruiting

Study of PF-07275315 to evaluate its effectiveness and safety in adults with moderate-to-severe asthma who have high levels of eosinophils in their blood

Investigational

Study of PF-07275315 to evaluate its effectiveness and safety in adults with moderate-to-severe asthma who have high levels of eosinophils in their blood

Investigational

Poland

Participants:18–64 years · 65+ years
Sponsor:Pfizer Inc.

Contact Research Centre

B-cell small lymphocytic lymphoma refractory+1

Recruiting

Study of sonrotoclax plus obinutuzumab or rituximab compared to venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

Registered drugNo placebo

Study of sonrotoclax plus obinutuzumab or rituximab compared to venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Obinutuzumab
Sponsor:BeOne Medicines AG

Contact Research Centre

Acromegaly

Recruiting

Study of Debio 4126, a new octreotide formulation, compared to placebo in patients with acromegaly who were previously treated with somatostatin analogs

Registered drug

Study of Debio 4126, a new octreotide formulation, compared to placebo in patients with acromegaly who were previously treated with somatostatin analogs

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Lanreotide
Sponsor:Debiopharm International S.A.

Contact Research Centre

Other cities in Poland

The busiest research cities in the country

All 236 cities in Poland

Clinical research in Swidnica

What the registry says about research in the country

01 Inflammatory Conditions

Innovative research focusing on inflammatory disorders, including trials evaluating new treatments for psoriatic arthritis and rheumatoid arthritis. Studies aim to assess novel therapeutic approaches using biologics and targeted medications.

Psoriatic Arthritis Studies
Rheumatoid Arthritis Treatment
Inflammatory Disease Management

Advanced therapies being tested to improve patient outcomes and quality of life.

02 Gastrointestinal Research

Comprehensive studies investigating treatments for inflammatory bowel diseases, including trials for Crohn's Disease and ulcerative colitis. Research focuses on novel therapeutic agents and long-term disease management.

Crohn's Disease Therapies
Ulcerative Colitis Treatments
Long-term Disease Management

Multiple trials exploring innovative approaches to treating gastrointestinal conditions.

03 Metabolic and Pain Management

Studies addressing obesity, knee osteoarthritis, and chronic pain conditions. Research includes evaluation of new medications for weight management and innovative approaches to pain relief.

Weight Management Therapies
Osteoarthritis Treatment
Pain Management Solutions

Cutting-edge research combining multiple therapeutic approaches for complex conditions.

04 Specialty Conditions

Focused research on unique conditions including thyroid eye disease, chronic spontaneous urticaria, and rotator cuff tendinopathy. Studies aim to develop targeted treatments for these specific medical needs.

Endocrine Disorders
Autoimmune Conditions
Musculoskeletal Treatments

Specialized therapeutic approaches for distinct medical conditions.

Back to Poland All countries